{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:17:31Z","timestamp":1785251851647,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Functional cure of chronic hepatitis B (CHB) is the optimal goal of antiviral therapy. This study evaluates the functional cure rates in a large cohort treated with interferon (IFN\u03b1) and explores baseline predictors to optimize personalized treatment strategies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective study included CHB patients treated with IFN monotherapy or IFN combined with nucleos(t)ide analogs at Beijing You\u2019an Hospital from 2008 to 2023. Patients were categorized into functional cure (FC) and non-functional cure (NFC) groups based on treatment outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 5288 patients, 887 (16.8%) achieved functional cure. FC patients had significantly lower baseline HBsAg, HBV DNA, and HBeAg positivity compared to NFC patients. Kaplan-Meier analysis revealed cumulative functional cure rates of 10.6%, 25.7%, and 39.9% at 48, 96, and 144 weeks, respectively. Multivariate logistic regression analysis identified lower baseline HBsAg levels, female, HBeAg negativity, lower \u03b3-GT levels, and higher FT3 and FT4 levels as factors associated with higher functional cure rates. Patients with HBsAg &amp;lt;100 IU\/ml had a cure rate of 58.8% within 96 weeks, compared to 11.1% for those with &amp;gt;1500 IU\/ml.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Early HBsAg decline is critical for functional cure. Female patients, HBeAg-negative status, and baseline HBsAg &amp;lt;100 IU\/mL predict higher success rates.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcimb.2025.1615327","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:23:31Z","timestamp":1750397011000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Determinants of functional cure in interferon-treated chronic hepatitis B: a retrospective cohort analysis of HBsAg dynamics and clinical predictors"],"prefix":"10.3389","volume":"15","author":[{"given":"Daqiong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianru","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zichen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/s2468-1253(22)00124-8","article-title":"Global, regional, and national burden of hepatitis B, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1136\/gut.2005.089722","article-title":"Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B","volume":"56","author":"Bonino","year":"2007","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1002\/hep.29213","article-title":"A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha","volume":"66","author":"Cao","year":"2017","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1111\/apt.14862","article-title":"A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B","volume":"48","author":"Chan","year":"2018","journal-title":"Aliment Pharmacol. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.cgh.2011.08.029","article-title":"Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection","volume":"10","author":"Chen","year":"2012","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1111\/jvh.13722","article-title":"Real-world study on HBsAg loss of combination therapy in HBeAg-negative chronic hepatitis B patients","volume":"29","author":"Chu","year":"2022","journal-title":"J. Viral Hepat"},{"key":"B7","doi-asserted-by":"publisher","first-page":"306.e7","DOI":"10.1016\/j.cmi.2017.07.016","article-title":"Predictive role of serum HBsAg and HBcrAg kinetics in patients with HBeAg-negative chronic hepatitis B receiving pegylated interferon-based therapy","volume":"24","author":"Chuaypen","year":"2018","journal-title":"Clin. Microbiol. Infect."},{"key":"B8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J. Hepatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/jvh.13599","article-title":"Mean HBsAg decline at week 24 of PEG-IFN-based treatment predicts subsequent rate of HBsAg clearance - suggesting a valuable endpoint for early development HBV trials","volume":"28","author":"De Ridder","year":"2021","journal-title":"J. Viral Hepat"},{"key":"B10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41581-023-00787-w","article-title":"Mechanisms and consequences of sex differences in immune responses","volume":"20","author":"Dunn","year":"2024","journal-title":"Nat. Rev. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1136\/gutjnl-2024-332182","article-title":"High accuracy model for HBsAg loss based on longitudinal trajectories of serum qHBsAg throughout long-term antiviral therapy","volume":"73","author":"Fan","year":"2024","journal-title":"Gut"},{"key":"B12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/jvh.13918","article-title":"Addition of PEG-interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic hepatitis B: Multicentre Randomized Trial (PAS Study)","volume":"31","author":"Farag","year":"2024","journal-title":"J. Viral Hepat"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1016\/j.jhep.2023.06.002","article-title":"Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: Report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference","volume":"79","author":"Ghany","year":"2023","journal-title":"J. Hepatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1016\/j.immuni.2023.10.008","article-title":"Sex hormone signaling and regulation of immune function","volume":"56","author":"Hoffmann","year":"2023","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41575-023-00760-9","article-title":"Global burden of hepatitis B virus: current status, missed opportunities and a call for action","volume":"20","author":"Hsu","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1007\/s12072-024-10648-8","article-title":"Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-\u03b1: a systematic review and meta-analysis","volume":"18","author":"Jiang","year":"2024","journal-title":"Hepatol. Int."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000586","article-title":"Rapid decline rather than absolute level of HBsAg predicts its seroclearance in untreated chronic hepatitis B patients from Taiwanese communities","volume":"14","author":"Lin","year":"2023","journal-title":"Clin. Transl. Gastroenterol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s12072-020-10099-x","article-title":"Effect of combination treatment based on interferon and nucleos(t)ide analogues on functional cure of chronic hepatitis B: a systematic review and meta-analysis","volume":"14","author":"Liu","year":"2020","journal-title":"Hepatol. Int."},{"key":"B19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12902-023-01371-w","article-title":"Analysis of clinical characteristics of thyroid disorders in patients with chronic hepatitis B treated with pegylated-interferon alpha","volume":"23","author":"Liu","year":"2023","journal-title":"BMC Endocr. Disord."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/03000605211025139","article-title":"Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with \u03b1-interferon","volume":"49","author":"Luo","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s11739-020-02622-7","article-title":"Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg","volume":"16","author":"Mimura","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1002\/cphy.c200003","article-title":"The role of thyroid hormone in the innate and adaptive immune response during infection","volume":"10","author":"Rubingh","year":"2020","journal-title":"Compr. Physiol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2024.2404965","article-title":"Association of hepatitis B core antibody level and hepatitis B surface antigen clearance in HBeAg-negative patients with chronic hepatitis B","volume":"15","author":"Wang","year":"2024","journal-title":"Virulence"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.894410","article-title":"Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-\u03b1 in NA-suppressed chronic hepatitis B patients","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jhep.2021.11.024","article-title":"How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development","volume":"76","author":"Wong","year":"2022","journal-title":"J. Hepatol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.3748\/wjg.v26.i13.1525","article-title":"Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen \u2264 1500 IU\/mL: An observational study","volume":"26","author":"Wu","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1007\/s12072-024-10666-6","article-title":"Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis","volume":"18","author":"Zhang","year":"2024","journal-title":"Hepatol. Int."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1615327\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T05:23:32Z","timestamp":1750397012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2025.1615327\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,20]]},"references-count":27,"alternative-id":["10.3389\/fcimb.2025.1615327"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2025.1615327","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,20]]},"article-number":"1615327"}}